Abstract
Only about 36% of Multiple Sclerosis (MS) patients are currently treated with
MS drugs, this percentage is expected to increase to 56% by 2014 as new oral
MS therapies are launched, which shows bright opportunity for oral drugs in
multiple sclerosis market. The injectables market is big but leaves certain
side effect which brings the possibility for the oral drugs to succeed. It is
expected that oral drugs will bring some ease for the patients. In Canada the
prevalence rate of MS is the highest with closely followed by United States
which is the second most affected region with increasing death rates of MS
patients. Also the prevalence rate in Germany, Norway and Hungary is high. In
2008 the MS treatment market has shown good results despite the slowdown in US
and with this success the probability for further growth has increased.
Gender has become a dominant factor in MS during the last decades. The studies
have proved that MS prevalence rate is higher in women than man, but the cause
of the disease has not been found. MS is the fourth leading cause of
disability among American women. Early Age Smoking is also one of the major
environmental factors which have increased the chances of MS disease. MS is
slowly spreading its reach in the Asian regions. Asia can be a potential
market in future.
This report analyses the global multiple sclerosis market demand and potential
opportunities prevailing in the market. It gives an overview of the disease
and prevalence worldwide, also covers the total market for MS treatment. It
presents global MS injectable market growth and discussion of various
medicines market share. The report also focuses on the growth of the industry
in United States. It gives an overview of the trends and opportunities present
in the industry. It also analyses competition in the market with an overview
of industry players and their business strategies.
| 
View Cart
